# Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386

> **NCT00832169** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 6 (estimated)

## Conditions studied

- Pain

## Interventions

- **DRUG:** AZD1386

## Key facts

- **NCT ID:** NCT00832169
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** —
- **Final completion:** 2009-02
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2009-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832169, "Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00832169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*